Can Semaglutide (GLP-1) Affect Your Period? A Complete Guide
Not directly, in the way a hormonal medicine does. Semaglutide (GLP-1) is a GLP-1 receptor agonist for type 2 diabetes and medical weight management. It contains no oestrogen or progesterone and has no proven direct action on ovulation, so the period changes people notice are mostly downstream effects of weight loss and improved insulin sensitivity. This overview summarises what the evidence says, and links to seven focused guides that go deeper on each topic. [1, 2]
Talk to a Karespot doctor →
Can Semaglutide (GLP-1) Affect Your Period?
Not directly, in the way the pill does. Semaglutide is not a hormone and contains no oestrogen or progesterone, so the period changes people report are mostly downstream of the weight loss and metabolic improvement it causes, not a proven direct action on the ovaries. GLP-1 receptors are present in reproductive tissue, so a direct effect cannot yet be fully ruled out, but the dominant, well-supported explanation is the indirect, weight-driven one.
Unlike a hormonal contraceptive or a fertility treatment, semaglutide does not carry reproductive hormones and is not designed to act on the cycle. What it does change is body weight, body fat, insulin sensitivity and energy balance, and the reproductive system is sensitive to all of those. So when a period shifts during treatment, it is usually your body responding to metabolic change rather than the medicine working on your ovaries. The chain below traces how that indirect route runs, step by step, and notes why a direct hormonal action is not the explanation. [1, 2]
What Changes Do People Actually Notice?
Both more regular and temporarily less regular cycles are reported. People with obesity, insulin resistance or PCOS often see more regular cycles as their metabolism improves, while others notice temporary irregularity during rapid weight loss. Many notice no change at all. Post-marketing safety databases have flagged reports of heavier or irregular bleeding as signals that warrant study, which is different from proof that the drug is the cause.
The most consistent, welcome pattern is in PCOS and insulin resistance, where lower body fat and better insulin sensitivity can reduce androgen excess and support more regular ovulation. Reports of heavier or irregular bleeding do exist in pharmacovigilance data, but because obesity itself changes cycle regularity and rapid fat loss shifts oestrogen metabolism, these reports can be confounded, which is exactly why they need careful research rather than alarm. [3, 6]
If a cycle becomes more regular, ovulation may have returned, and with it the possibility of pregnancy. Semaglutide is not a contraceptive and is not recommended in pregnancy. It is usually stopped at least two months before conception, so if you are not planning a pregnancy, reliable contraception matters more, not less. [4, 5]
Explore the Seven Guides
Use this overview as your starting point, then follow the guide that matches your question. Each one is medically reviewed and goes deeper than this summary.
Managing weight and your cycle together?
Karespot's Internal Medicine specialists provide physician-led weight management, and our Endocrinologists support hormonal conditions such as PCOS and insulin resistance, so your metabolic and reproductive health are managed together.
Check your eligibility → Doctor-led care, available across IndiaFrequently Asked Questions
Can semaglutide (GLP-1) affect your period?
Will my periods become more regular or less regular on semaglutide?
Should I stop semaglutide if my periods change?
Does semaglutide change oestrogen or progesterone levels?
Can semaglutide affect fertility?
When should I see a doctor about period changes on semaglutide?
Kommu S, Whitfield P. Semaglutide. StatPearls. StatPearls Publishing; updated 2024.
ncbi.nlm.nih.gov/books/NBK603723Sills ES, Harrity C, Chu HI, et al. Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development. Reprod Biol Endocrinol. 2025;23:116.
doi.org/10.1186/s12958-025-01435-7Monney M, Mavromati M, Leboulleux S, Gariani K. Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review. Endocr Connect. 2025;14(5):e240529.
doi.org/10.1530/EC-24-0529Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. Fertil Steril. 2021;116(5):1266-1285.
asrm.org | Obesity and reproduction: a committee opinion (2021)Semaglutide Prescribing Information. U.S. Food & Drug Administration; 2023. (Discontinue at least 2 months before a planned pregnancy; not recommended during pregnancy.)
accessdata.fda.gov | Semaglutide Prescribing Information (2023)Menstrual adverse events with GLP-1 receptor agonists: a disproportionality and Bayesian analysis of the FDA Adverse Event Reporting System through March 2026. Reported via Medscape, July 2026.
medscape.com | Menstrual events with GLP-1 RAsDr. Prakrati Garg is a Research Associate and published researcher in Biotechnology at Shoolini University, and Content Strategist at Karespot. With expertise in herbal drug development, nanotechnology and drug delivery systems, she brings a rigorous scientific approach to Karespot's health and wellness content.
Dr. Sana Umar is an Assistant Professor at Doon Medical College and Medical Reviewer at Karespot. A Clinical Pathologist with FRCP credentials and NMC registration (Reg. 8506), she ensures all clinical content aligns with current prescribing guidelines and evidence-based best practices in GLP-1 therapy and women's metabolic health.
Obesity and metabolic health are complex, and navigating them alone is harder still.
That is why Karespot brings you expert, doctor-led care that is never limited to a single speciality. Depending on what your body needs, you are supported by the right specialists and super-specialists, working together across India.
Medical Disclaimer: This article is for general information and education. It is not a substitute for personalised medical advice. Semaglutide (GLP-1) is a prescription medicine; do not start, stop or change your dose without consulting a qualified healthcare professional. If you are pregnant, planning a pregnancy, or concerned about your menstrual cycle, speak to your doctor.
